ImExHS stock edges higher as new Colombia oncology deal marks A$1.4m ARR breakthrough

ImExHS Limited (ASX: IME) shares edged up by 2.13% to A$0.24 in afternoon trading on 26 September 2025, offering a modest reprieve for shareholders after a volatile year that saw the stock lose half its value. The Australian healthcare technology company, with a market capitalisation of just A$12.94 million, remains one of the smaller players on the ASX. Yet, its latest win — a contract with Colombian oncology group Oncolife worth around A$1.4 million in new annual recurring revenue — could mark a turning point in its long-term strategy.

The contract underlines ImExHS’s hybrid business model, blending medical imaging software with radiology services to serve cancer patients who require advanced diagnostics. While still a microcap, the company is working to prove that its SaaS-driven approach and specialised service delivery can unlock higher-margin growth.

What does the new Oncolife contract mean for ImExHS’s revenue outlook?

ImExHS confirmed it has signed a material new contract with Oncolife, a cancer-focused healthcare provider operating a flagship hospital in north Bogotá along with centres in Villavicencio and Zipaquirá. These sites treat oncology patients and require sophisticated diagnostic procedures, where radiology services are central to effective care.

The contract includes provision of radiology services supported by ImExHS’s RIS/PACS platform, a patient portal, and selected AI diagnostic layers. The arrangement, effective immediately, runs for an initial one-year term and is expected to deliver approximately A$1.4 million in new annual recurring revenue. Crucially, the deal bundles together software subscriptions and services under the company’s revised 2024 pricing model, which was designed to improve profitability per client.

For a business of ImExHS’s size, a single deal of this magnitude is material. With a market cap of under A$13 million, the contract represents more than 10% of the company’s current valuation. That scale alone underscores how contract execution and renewals can directly shape investor confidence.

How has ImExHS’s share price and investor sentiment evolved over the past year?

Despite the modest uplift, ImExHS shares remain close to their 52-week low of A$0.22 and well below the high of A$0.46. The one-year return of negative 50% reflects both challenges in delivering consistent profitability and broader investor caution toward microcap healthtech names. Trading volumes are moderate, with 161,250 shares exchanged on 26 September, reflecting relatively thin liquidity for the 53.92 million ordinary shares outstanding.

Institutional flows into ImExHS stock have been limited in 2025. Foreign institutional investors (FIIs) have generally favoured larger SaaS and healthtech companies, while domestic institutional investors (DIIs) have leaned toward established radiology service providers with diversified global footprints. As a result, the bulk of trading activity appears to be retail-driven, leaving the stock more vulnerable to volatility tied to contract news or quarterly earnings.

From a market sentiment standpoint, the Oncolife announcement is a positive catalyst, but investors are cautious. Analysts point out that sustainable share price recovery will require proof of contract renewals, broader adoption of its SaaS platforms, and tangible margin improvements.

Why is radiology and SaaS imaging software central to ImExHS’s strategy?

ImExHS was founded in 2012 with a vision to deliver cloud-based, vendor-neutral imaging solutions. Its product suite includes Picture Archiving and Communications System (PACS), Radiology Information System (RIS), Cardiology Information System (CIS), and Anatomical Pathology Laboratory Information System (APLIS). All solutions are zero-footprint SaaS platforms, requiring no local installation, which reduces costs for healthcare providers and enables faster scaling across geographies.

This positioning is particularly relevant in emerging markets where hospitals often face budget constraints and infrastructure limitations. By delivering advanced imaging software via the cloud, ImExHS allows healthcare providers to access high-end tools without heavy upfront investment.

The Oncolife contract is a textbook example of this strategy at work. By combining radiology services with integrated software and AI support, the company is embedding itself deeper into oncology workflows. This creates not only service revenue but also sticky software subscriptions that can deliver long-term recurring income.

How does the Latin American healthcare market shape ImExHS’s opportunity?

Although ImExHS now operates in 18 countries, Latin America remains its strongest base. The region is undergoing rapid demand growth for diagnostic imaging as cancer prevalence rises and governments invest in upgrading healthcare infrastructure. Yet, resource constraints mean hospitals are increasingly seeking cost-effective SaaS solutions over traditional installed systems.

By partnering with a leading oncology provider like Oncolife, ImExHS is consolidating its leadership in Colombia, one of the region’s largest healthcare markets. Oncology and cardiology are high-value segments within radiology, where margins are more attractive compared to general outpatient imaging. Success here can open doors to expansion into neighbouring markets and other specialised segments.

What role do AI diagnostic layers play in ImExHS’s product differentiation?

Artificial intelligence is becoming a critical component of radiology worldwide, with applications in detecting anomalies, reducing reporting time, and improving accuracy. ImExHS has integrated AI modules into its RIS/PACS offering to support radiologists in oncology cases, where early and precise diagnosis is vital.

For Oncolife, AI-powered imaging can help improve outcomes by catching subtle lesions and supporting treatment monitoring. For ImExHS, it creates a unique selling point in competitive tenders, enabling the company to differentiate itself from regional competitors still reliant on conventional systems.

This aligns with global trends where leading imaging players such as Siemens Healthineers and GE Healthcare are embedding AI within their platforms. ImExHS is bringing a similar model to emerging markets, albeit at a smaller scale, positioning itself as an early mover in accessible AI-driven imaging.

How is ImExHS using its 2024 pricing model to boost margins and secure higher recurring revenue?

The 2024 pricing model adopted by ImExHS is designed to capture more value from each client engagement. By bundling radiology services with software and AI modules, the company aims to lift gross margins and ensure recurring revenue streams.

Previously, microcap providers often competed mainly on service price, limiting margin expansion. Now, with software playing a greater role, ImExHS can better monetise its intellectual property and reduce its reliance on variable service delivery costs. If successfully implemented across new and renewed contracts, this model could underpin a stronger financial profile.

What risks could limit ImExHS’s growth even after securing the Oncolife oncology contract?

While the Oncolife contract is a positive milestone, several risks remain. The one-year initial term means the company must deliver high-quality service to secure renewal and potentially expand the relationship. Any missteps in delivery could jeopardise renewal and reduce revenue visibility.

Currency volatility between the Australian dollar and Colombian peso could also impact reported results, given that much of ImExHS’s revenue is generated in Latin America. In addition, competition from larger, better-capitalised imaging companies in the US and Australia remains a headwind.

Finally, with a small market cap and limited trading liquidity, ImExHS stock remains exposed to sharp swings on news flow, making it less attractive to risk-averse institutions.

What are the final takeaways for investors on ImExHS stock, market sentiment, and long-term growth plans?

ImExHS Limited (ASX: IME) has struggled to maintain investor confidence over the past year, but its A$1.4 million contract win with Oncolife signals concrete progress in its strategy. By combining SaaS imaging solutions, radiology services, and AI diagnostic modules, the company is strengthening its presence in high-value oncology care across Latin America.

While institutional sentiment remains cautious, retail investors may view the stock as a speculative healthcare technology play with meaningful upside if execution continues. The new pricing model, if proven successful, could help expand margins and attract longer-term investors. For now, the Oncolife deal represents both an immediate revenue boost and a critical test case for ImExHS’s ability to scale in specialised healthcare markets.